Literature DB >> 34165816

Innovative therapies based on molecular orientation in patients with Relapse and Refractory diffuse large B cell lymphoma, results of LNH-EP1 study.

Clémentine Sarkozy1,2, Jean-Marie Michot1, Cyril Quivoron3, Valérie Camara-Clayette3, Alina Danu4, Julien Lazarovici4, Yolla El-Dakdouki4, Khalil Saleh4, David Ghez4, Julien Rossignol4, Capucine Baldini1, Julia Arfi-Rouche5, Patricia Romano-Martin1, Lambros Tselikas5, Andrea Varga1, Anas Gazzah1, Antoine Hollebecque1, Ludovic Lacroix6, Rastislav Bahleda1, Hélène Lecourt3, Veronique Vergé6, Wasilla Rahali4, Sophie Cotteret6, Jean-Charles Soria1, Peggy Dartigues6, Christophe Massard1, Vincent Ribrag1,3,4,2.   

Abstract

Entities:  

Year:  2021        PMID： 34165816     DOI： 10.1002/ajh.26280

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  1 in total

1.  Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma.

Authors:  Cyril Quivoron; Anthony Tarabay; Jean-Marie Michot; Arnaud Pagès; Hélène Lecourt; Anne Aupérin; Alina Danu; Julien Lazarovici; Julien Rossignol; David Ghez; Peggy Dartigues; Véronique Vergé; Christophe Massard; Valérie Camara-Clayette; Vincent Ribrag; Clémentine Sarkozy
Journal:  Haematologica       Date:  2022-08-01       Impact factor: 11.047
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.